You are viewing: Rest Of Europe Humanized Mouse and Rat Model Market analysis

The Rest Of Europe Humanized Mouse and Rat Model Market was valued at $9.6 Million in 2025 and projected to reach to $13.9 Million by 2030, representing a compound annual growth rate of 7.8%. Rest Of Europe's humanized mouse and rat model market is positioned for steady expansion as regional research institutions increasingly adopt advanced preclinical models for drug development.

Rest Of Europe Humanized Mouse and Rat Model Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Rest Of Europe Humanized Mouse and Rat Model Market Trends and Insights

  • Rest Of Europe represents a significant but emerging segment within the broader European preclinical research landscape, driven by increasing investment in drug discovery and personalized medicine initiatives across the region.
  • The market in Rest Of Europe is characterized by growing adoption of advanced in vivo models among contract research organizations, academic institutions, and pharmaceutical companies seeking to improve translational research outcomes. Rest Of Europe's 7.8% compound annual growth rate reflects rising demand for humanized models in oncology, immunology, and infectious disease research.
  • Rest Of Europe benefits from collaborative research networks and regulatory support for alternative testing methodologies that reduce reliance on traditional animal models.
  • The forecast period through 2030 indicates Rest Of Europe will continue to capture market share as biotechnology sectors mature and funding for precision medicine research increases across the region..

Key Market Statistics

  • CAGR (2025-2030) 7.8% CAGR
  • Market Size, 2025 ~USD 9.6 Million
  • Forecast, 2030 ~USD 13.9 Million
  • Country Rest Of Europe

Rest Of Europe Humanized Mouse and Rat Model Market Overview

Steady Regional Growth :

Rest Of Europe's humanized mouse and rat model market is expanding at a 7.8% CAGR, slightly below the global average of 8.2%, reflecting emerging adoption patterns across smaller European markets and research institutions.

Emerging Research Investment :

Increasing funding for drug discovery and personalized medicine initiatives across Central, Eastern, and Southern European countries is driving demand for advanced preclinical models in academic and biotech research centers.

Market Valuation Trajectory :

The market is valued at USD 9.6 million in 2025 and is projected to reach USD 13.9 million by 2030, representing a 44.8% absolute growth over the five-year forecast period.

Emerging Segment Status :

Rest Of Europe represents a significant but developing segment within the broader European preclinical research landscape, with untapped potential in countries establishing advanced research infrastructure.

Rest Of Europe Humanized Mouse and Rat Model Market Dynamics

  • Growing government support for life sciences research, coupled with rising collaborations between academic centers and pharmaceutical companies, is accelerating market penetration across the region.
  • The shift toward personalized medicine and precision therapeutics is creating sustained demand for sophisticated animal models. Key growth drivers include expanding biotech ecosystems in emerging European markets, increased outsourcing of preclinical research from Western Europe, and rising awareness of humanized models' advantages in predicting human drug responses.
  • However, regulatory variations across countries and competition from established Western European markets may moderate growth rates.
  • Strategic investments in research infrastructure and talent development will be critical for capturing emerging opportunities in this developing segment..

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Key Takeaways

    • Rest Of Europe's humanized mouse and rat model market is valued at USD 9.6 million in 2025 and expected to reach USD 13.9 million by 2030, representing a 7.8% CAGR.
    • Rest Of Europe demonstrates strong adoption of humanized models in oncology, immunology, and infectious disease research applications.
    • Rest Of Europe benefits from robust academic research infrastructure and collaborative networks that support preclinical model development.
    • Rest Of Europe's growth trajectory is supported by increasing pharmaceutical R&D investment and regulatory emphasis on alternative testing methods.

    Humanized Mouse and Rat Model Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS (CROS AND CDMOS) (End User)
    Forecast Period 2025–2030
    Growth Rate CAGR of 8.2% from 2025 to 2030
    Largest Segment HUMANIZED MOUSE MODELS (Type)
    Market Size Base Year (Billions) ~USD 0.28 (2025)
    Revenue Forecast (Billions) ~USD 0.41 (2030)
    Segments Covered Type, End User, Application

    Rest Of Europe Humanized Mouse and Rat Model Market Report Segmentation

    3 segment dimensions are covered across the global market.

    By Type

    • Blt Humanized Mouse Models
    • Cd34 Humanized Mouse Models
    • Cell-Based Humanized Mouse Models
    • Genetic Humanized Mouse Models
    • Humanized Mouse Models
    • Humanized Rat Models
    • Pbmc Humanized Mouse Models

    By End User

    • Academic & Research Institutes
    • Academic And Research Institutes
    • Contract Research Organizations And Contract Development And Manufacturing Organizations (Cros And Cdmos)
    • Cros & Cdmos
    • Cros And Cdmos
    • Pharmaceutical & Biotechnology Companies
    • Pharmaceutical And Biotechnology Companies

    By Application

    • Hematopoiesis
    • Immunology And Infectious Diseases
    • Neuroscience
    • Oncology
    • Other Applications
    • Toxicology

    Target Audience

    • Pharmaceutical & Biotech Companies : Need Rest Of Europe market data to evaluate preclinical outsourcing opportunities, identify regional CRO partnerships, and plan drug development strategies in emerging European markets.
    • Contract Research Organizations (CROs) : Require regional market intelligence to assess expansion opportunities, benchmark service offerings against competitors, and capture growing demand for humanized model services in developing European markets.
    • Academic & Research Institutions : Seek market insights to justify funding requests, understand regional research trends, and identify collaboration opportunities with industry partners investing in preclinical research across Rest Of Europe.
    • Animal Model Suppliers & Vendors : Need Rest Of Europe-specific data to identify distribution channels, assess market demand, and develop regional sales strategies for humanized mouse and rat models in emerging European segments.
    • Healthcare Investors & Consultants : Require detailed regional market analysis to evaluate investment opportunities, assess growth potential, and provide strategic recommendations for clients targeting Rest Of Europe's emerging preclinical research sector.

    Key Companies in the Rest Of Europe Humanized Mouse and Rat Model Market

    CompanyHQOwnershipStrongest segments
    CHARLES RIVER LABORATORIESUnited StatesPublic CompanyResearch Models and Services,Discovery and Safety Assessment,Manufacturing Solutions,
    THE JACKSON LABORATORYUnited StatesFoundation/Charitable InstitutionMouse breeding and colony management,Phenotyping, efficacy testing, and genetic research services,Genetic resources, software, and data,
    INOTIVUnited StatesPublic CompanyResearch Models and Services (RMS),Discovery and Safety Assessment (DSA) Services,BASi Scientific Instruments and Software,
    GENOWAYFrancePublic CompanyCustom mouse models (KO/KI and humanized),Custom rat models,Engineered cell lines,
    JSR CORPORATIONJapanPrivate CompanyDigital Solutions (lithography, photoresists, CMP, display and packaging materials),Plastics / Synthetic Resins (ABS, AES, AS, ASA and related resins),Life Sciences (diagnostic and research reagents, bioprocess materials, drug discovery support),
    CHAMPIONS ONCOLOGY, INC.United StatesPublic CompanyTumorgraft / PDX-based translational oncology services,Personalized cancer care services,Lumin Bioinformatics and data-driven software,
    ONCODESIGN SERVICESFrancePublic CompanyPrecision oncology and immuno-oncology (OPM-101, OPM-102),Neurodegeneration (OPM-201, Parkinson’s),Radiotheranostic portfolio for digestive and pancreatic cancers,

    CHARLES RIVER LABORATORIES

    Charles River Laboratories is a public company founded in 1947 in the United States with 19,000 employees.

    THE JACKSON LABORATORY

    The Jackson Laboratory is a foundation-based charitable institution founded in 1929 in the United States with 2,100 employees.

    INOTIV

    Inotiv is a public company founded in 1974 in the United States with 1,996 employees.

    GENOWAY

    Genoway is a public company founded in 1999 in France with 157 employees.

    JSR CORPORATION

    JSR Corporation is a private company founded in 1948 in Japan with 7,997 employees.

    CHAMPIONS ONCOLOGY, INC.

    Champions Oncology, Inc. is a public company founded in 1985 in the United States with 214 employees.

    ONCODESIGN SERVICES

    Oncodesign Services is a public company founded in 1995 in France.

    Reasons to Buy this Report

    • Regional Market Segmentation : Gain detailed insights specific to Rest Of Europe's market dynamics, excluding Western European powerhouses, to identify untapped opportunities in emerging research markets and developing biotech ecosystems.
    • Growth Trajectory Analysis : Understand the 7.8% CAGR growth pattern and USD 4.3 million market expansion opportunity from 2025-2030, enabling strategic planning for market entry or expansion in this emerging segment.
    • Competitive Positioning : Benchmark your organization against regional competitors and identify market gaps in Central, Eastern, and Southern European countries where humanized model adoption is still developing.
    • Investment Decision Support : Make informed decisions about R&D investments, partnerships, and facility expansion in Rest Of Europe based on validated market size projections and regional growth drivers.
    • Strategic Market Entry : Develop targeted go-to-market strategies for Rest Of Europe by understanding regional research funding trends, regulatory landscapes, and emerging demand from academic and biotech institutions.

    Frequently asked questions

    What is the market size of humanized mouse and rat models in Rest Of Europe?

    Rest Of Europe's humanized mouse and rat model market was valued at USD 9.6 million in 2025 and is forecast to reach USD 13.9 million by 2030.

    What is the expected growth rate for Rest Of Europe's humanized model market?

    Rest Of Europe's market is projected to grow at a compound annual growth rate (CAGR) of 7.8% from 2025 to 2030.

    Which therapeutic areas drive demand in Rest Of Europe?

    Rest Of Europe shows strong demand for humanized models in oncology, immunology, and infectious disease research, reflecting regional research priorities.

    What factors support market growth in Rest Of Europe?

    Rest Of Europe's growth is driven by increased pharmaceutical R&D investment, regulatory support for alternative testing methods, and expanding academic research networks.

    Who are the primary end-users in Rest Of Europe?

    Rest Of Europe's market is served by contract research organizations, academic institutions, pharmaceutical companies, and biotechnology firms engaged in preclinical research.

    RESEARCH METHODOLOGY

    The research study used secondary sources, directories, and databases to identify and collect valuable information to analyze the global humanized mouse and rat model market. Widespread interviews were conducted with various primary participants, including key industry members, subject-matter experts (SMEs), C-level managers of leading market players, and industry consultants, to obtain and verify qualitative and quantitative information and evaluate the growth scenarios of the market. The global market size was estimated through secondary research (top-down and bottom-up), followed by data triangulation with inputs from industry experts to determine the final market size.

    Secondary Research

    Secondary research was used to identify and collect information for the technical, market-oriented, and commercial study of the humanized mouse and rat model market. The secondary sources used for this study include the American Association for Cancer Research (AACR), American Association for Laboratory Animal Science (AALAS), European Society for Medical Oncology (ESMO), European Association for Cancer Research (EACR), Humanized Mouse Resource (HMR), National Center for Biotechnology Information (NCBI), and Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC).

    Academic Journals and Company Websites; corporate & regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines & research journals; press releases; and trade, business, and professional associations were also used to obtain major information about key market players and market segmentation corresponding to industry trends, regional/country-level markets, market developments, and technology prospects. Secondary data was collected and analyzed to determine the market size of the global humanized mouse and rat model market, which was further validated through primary research.

    Primary Research

    Primary research was conducted after acquiring basic knowledge about the global humanized mouse and rat model market through secondary research. A series of primary interviews were conducted with market experts from the demand side, including professionals from the pharmaceutical and biopharmaceutical industries and academic institutions. Additionally, interviews were held with individuals from the supply side, such as C-level and D-level executives, product managers, and marketing and sales managers from key manufacturers, distributors, and channel partners. The primary interviews were conducted across North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Approximately 80% and 20% of the primary interviews were conducted with supply-side and demand-side participants. This data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

    The breakdown of the primary respondents is given below.

    Humanized Mouse and Rat Model Market

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    Top-down and bottom-up approaches were used to estimate and validate the total size of the humanized mouse and rat model market. These methods were also used extensively to estimate the size of various subsegments in the market.

    Humanized Mouse and Rat Model Market

    Data Triangulation

    After determining the market size from the above estimation process, the total market was divided into several segments and subsegments. Where applicable, data triangulation and market breakdown procedures were employed to complete the overall market engineering process and determine the exact statistics for all segments and subsegments. The data was triangulated by studying various factors and trends from the demand and supply sides.

    Market Definition

    A humanized mouse and rat model is an immunodeficient organism genetically engineered to study immune responses to drugs or identify potential disease targets. These models are widely used to study human diseases and genes. Researchers in both academia and industry, along with clinicians, extensively use humanized mouse and rat models in their research applications. Humanized mouse and rat models are beneficial tools for immuno-oncology and infectious disease research. They have improved the ability to predict human responses to new therapeutics in clinical development.

    Stakeholders

    • Research and consulting firms
    • Biopharmaceutical manufacturers
    • Pharmaceutical manufacturers
    • Mouse model and service companies
    • Government and private research institutes
    • Manufacturers and suppliers of animal care products
    • Clinical research organizations (CROs)
    • Academic and research institutes
    • Venture capitalists
    • Laboratory animal care associations
    • Public and private animal health agencies

    Report Objectives

     

    To define, describe, and forecast the humanized mouse and rat model market by type, application, end user, and region

    To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)

    • To analyze the micromarkets1 concerning individual growth trends, prospects, and contributions to the overall humanized mouse and rat model market
    • To assess the opportunities for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments for North America, Europe, the Asia Pacific, Latin America, Middle East, and Africa
    • To profile the key players and analyze their market shares and core competencies2
    • To track and analyze competitive developments, such as product/service launches, partnerships, agreements, collaborations, and expansions
    • To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy

     

    Get the Full Humanized Mouse and Rat Model Market Report

    Full forecast, segment splits, and company analysis for all Humanized Mouse and Rat Model Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status